Main Article Content

Candace YW Lee
Savithiri Ratnapalan
Margaret Thompson
Paul C Nathan
Jordan Closs
Amy French
Angela Punnett
Facundo Garcia-Bournissen
Shinya Ito
Gideon Koren


5-HT3 receptor antagonists, child


A case of unusual reactions consisting of involuntary abnormal facial movements in a child following exposure to the 5-HT3 receptor antagonists for prophylaxis against chemotherapy-induced vomiting is presented. Potential mechanisms for these reactions are discussed.

Abstract 273 | PDF Downloads 83


1. Pasricha PJ. Treatment of disorders of bowel motility and water flux; antiemetics; agents used in biliary and pancreatic disease. In: Brunton LL, Lazo JS, Parker KL, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. New York: McGraw-Hill Companies, Inc.; 2006:983- 1008.
2. Dixon C, Colthup P, Serabjit-Singh C, et al. Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans. Drug Metab Dispos 1995;23:1225-30.
3. Kovac AL. Benefits and risks of newer treatments for chemotherapy-induced and postoperative nausea and vomiting. Drug Saf 2003;26:227-59.
4. GlaxoSmithKline. Prescribing information ZOFRAN® (ondansetron hydrochloride) injection Available at: http://wwwaccessdatafdagov/drugsatfda_docs/lab el/2006/020007s039,020403s016lblpdf Accessed June 19, 2009.
5. Blackwell CP, Harding SM. The clinical pharmacology of ondansetron. Eur J Cancer Clin Oncol 1989;25 Suppl 1:S21-4; discussion S5-7.
6. Saynor DA, Dixon CM. The metabolism of ondansetron. Eur J Cancer Clin Oncol 1989;25 Suppl 1:S75-7.
7. Schinkel AH, Wagenaar E, Mol CA, van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 1996; 97:2517-24.
8. Simpson KH, Murphy P, Colthup PV, Whelan P. Concentration of ondansetron in cerebrospinal fluid following oral dosing in volunteers. Psychopharmacology (Berl) 1992;109:497-8.
9. Nakamura H, Ariyoshi N, Okada K, Nakasa H, Nakazawa K, Kitada M. CYP1A1 is a major enzyme responsible for the metabolism of granisetron in human liver microsomes. Curr Drug Metab 2005; 6:469-80.
10. Pharmaceuticals R. Kytril® (granisetron hydrochloride) injection. Available at: http://wwwaccessdatafdagov/drugsatfda_docs/lab el/2005/020239s018lblpdf Accessed June 19, 2009.
11. The antiemetic efficacy and safety of granisetron compared with metoclopramide plus dexamethasone in patients receiving fractionated chemotherapy over 5 days. The Granisetron Study Group. J Cancer Res Clin Oncol 1993;119:555-9.
12. Lemerle J, Amaral D, Southall DP, Upward J, Murdoch RD. Efficacy and safety of granisetron in the prevention of chemotherapy-induced emesis in paediatric patients. Eur J Cancer 1991;27: 1081-3.
13. Aksoylar S, Akman SA, Ozgenc F, Kansoy S. Comparison of tropisetron and granisetron in the control of nausea and vomiting in children receiving combined cancer chemotherapy. Pediatr Hematol Oncol 2001;18:397-406.
14. Allen A, Crome P, Davie CC, et al. The pharmacokinetics of granisetron, a 5-HT3 antagonist in healthy young and elderly volunteers. Eur J Clin Pharmacol 1995;48:519- 20.
15. Berrak SG, Ozdemir N, Bakirci N, et al. A double-blind, crossover, randomized dosecomparison trial of granisetron for the prevention of acute and delayed nausea and emesis in children receiving moderately emetogenic carboplatin-based chemotherapy. Support Care Cancer 2007;15:1163-8.
16. Sprung J, Choudhry FM, Hall BA. Extrapyramidal reactions to ondansetron: Cross-reactivity between ondansetron and prochlorperazine? Anesth Analg 2003;96:1374-6.
17. Dobrow RB, Coppock MA, Hosenpud JR. Extrapyramidal reaction caused by ondansetron. J Clin Oncol 1991;9:1921.
18. Halperin JR, Murphy B. Extrapyramidal reaction to ondansetron. Cancer 1992;69:1275.
19. Garcia-del-Muro X, Cardenal F, Ferrer P. Extrapyramidal reaction associated with ondansetron. Eur J Cancer 1993;29A:288.
20. Ritter MJ, Goodman BP, Sprung J, Wijdicks EF. Ondansetron-induced multifocal encephalopathy. Mayo Clin Proc 2003;78:1150-2.
21. Tolan MM, Fuhrman TM, Tsueda K, Lippmann SB. Perioperative extrapyramidal reactions associated with ondansetron. Anesthesiology 1999;90:340-1.
22. Krstenansky PM, Petree J, Long G. Extrapyramidal reaction caused by ondansetron. Ann Pharmacother 1994;28:280.
23. Mathews HG, 3rd, Tancil CG. Extrapyramidal reaction caused by ondansetron. Ann Pharmacother 1996;30:196.
24. Stonell C. An extrapyramidal reaction to ondansetron. Br J Anaesth 1998;81:658.
25. Kumar N, Hu WT. Extrapyramidal reaction to ondansetron and propofol. Mov Disord 2009;24:312-3.
26. Ondansetron: Drug information. In: UpToDate Online: UpToDate, Inc.; 2009.
27. Ondansetron: Pediatric drug information. In: UpToDate Online: UpToDate, Inc; 2009.
28. Kwon P, Lefkowitz W. Neonatal extrapyramidal movements Pediatric Annals 2008;37:128-30.
29. Kwon P, Lefkowitz W. Neonatal extrapyramidal movements. Neonatal withdrawal due to maternal citalopram and ondansetron use. Pediatr Ann 2008;37:128-30.
30. Gebbia V, Testa A, Valenza R, Cannata G, Tirrito ML, Gebbia N. Oral granisetron with or without methylprednisolone versus metoclopramide plus methylprednisolone in the management of delayed nausea and vomiting induced by cisplatin-based chemotherapy. A prospective randomized trial. Cancer 1995;76:1821-8.
31. Hahlen K, Quintana E, Pinkerton CR, Cedar E. A randomized comparison of intravenously administered granisetron versus chlorpromazine plus dexamethasone in the prevention of ifosfamide-induced emesis in children. J Pediatr 1995;126:309-13.
32. Ohmatsu H, Eguchi K, Shinkai T, et al. A randomized cross-over study of high-dose metoclopramide plus dexamethasone versus granisetron plus dexamethasone in patients receiving chemotherapy with high-dose cisplatin. Jpn J Cancer Res 1994;85:1151-8.
33. Miyajima Y, Numata S, Katayama I, Horibe K. Prevention of chemotherapy-induced emesis with granisetron in children with malignant diseases. Am J Pediatr Hematol Oncol 1994;16:236-41.
34. Yarker YE, McTavish D. Granisetron. An update of its therapeutic use in nausea and vomiting induced by antineoplastic therapy. Drugs 1994;48:761-93.
35. Soukop M. Clinical experience with intravenous granisetron. Anticancer Drugs 1994;5:281-6.
36. Chevallier B. The control of acute cisplatininduced emesis--a comparative study of granisetron and a combination regimen of highdose metoclopramide and dexamethasone. Granisetron Study Group. Br J Cancer 1993;68:176-80.
37. Joss RA, Dott CS. Clinical studies with granisetron, a new 5-HT3 receptor antagonist for the treatment of cancer chemotherapy-induced emesis. The Granisetron Study Group. Eur J Cancer 1993; 29A Suppl 1:S22-9.
38. Diehl V. Fractionated chemotherapy--granisetron or conventional antiemetics? The Granisetron Study Group. Eur J Cancer 1992;28A Suppl 1:S21-8.
39. Kytril® granisetron HCl. e-CPS (Compendium of Pharmaceuticals and Specialties) 2009. Available at: http://www.pharmacists.ca/content/products/ecps _english.cfm Accessed June 19, 2009.
40. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
41. Avner M, Finkelstein Y, Hackam D, Koren G. Establishing causality in pediatric adverse drug reactions: use of the Naranjo probability scale. Paediatr Drugs 2007;9:267-70.
42. Kivisto KT, Kroemer HK, Eichelbaum M. The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br J Clin Pharmacol 1995;40: 523-30.
43. Dresser GK, Bailey DG. A basic conceptual and practical overview of interactions with highly prescribed drugs. Can J Clin Pharmacol 2002;9:191-8.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>